MSDC has a novel approach that could overcome the problems of existing insulin sensitizers while maintaining efficacy and providing great benefit to patients.
Kalamazoo, MI (PRWEB) February 17, 2011
Metabolic Solutions Development Company (MSDC), a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced today that it has appointed John M. Amatruda, M.D. as chair of the company’s Science and Medical Advisory Board (SMAB).
Amatruda was formerly vice president of clinical development for metabolism, atherosclerosis, and cardiovascular at Merck & Co., Inc., and served most recently as senior vice president and franchise head of Merck’s discovery research and drug development effort in diabetes and obesity.
“We are extremely pleased to have attracted a pharmaceutical research and development executive of Dr. Amatruda’s stature to chair our Science and Medical Advisory Board,” said Stephen Benoit, MSDC’s chief executive officer. “His extensive experience in academic medicine and his proven executive leadership in drug discovery and development will serve as an outstanding complement to the current members of our SMAB as well as the experience, expertise and vision of MSDC’s founders.”
Amatruda is board certified in internal medicine, endocrinology and metabolism. Prior to joining Merck, Amatruda was vice president of metabolic disorders research at Bayer Corporation. Amatruda worked in academic medicine at Yale University School of Medicine and the University of Rochester School of Medicine. Amatruda has a B.S. from Yale University and an M.D. from the Medical College of Wisconsin. He completed his internal medicine, and endocrinology and metabolism training at the Johns Hopkins Hospital.
“It is a pleasure to chair the Science and Medical Advisory Board at MSDC,” said Amatruda. “There is tremendous unmet medical need in the treatment of type 2 diabetes, especially in the area of insulin sensitizers. MSDC has a novel approach that could overcome the problems of existing insulin sensitizers while maintaining efficacy and providing great benefit to patients.”
Amatruda joins MSDC’s existing SMAB members: Jerry Colca, Ph.D., MSDC president, chief scientific officer and co-founder; Rolf Kletzien, Ph.D., MSDC senior vice president of research and co-founder; Douglas R. Morton Jr., Ph.D., former group vice president of technology acquisitions and operations for discovery research at Pharmacia Corporation; Charles F. Burant, M.D., Ph.D., the Dr. Robert C. and Veronica Atkins professor of metabolism at the University of Michigan Medical School; and William Baer, M.D., PharmD, executive director and chief medical officer of ClinXus and a longtime practitioner of internal medicine at Grand Valley Medical Specialists.
# # #